ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0876

Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis

Erin Balay1 and Susan Shenoi2, 1University of Washington, Seattle Children's Hospital, Seattle, WA, 2Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Access to care, Disease Activity, Epidemiology, Juvenile idiopathic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease in children. JIA disease course and prognosis varies significantly between its seven categories, and patients face the possibility of debilitating arthritis and deformity. Identification of patients at risk for severe and prolonged active disease is likely to affect treatment strategies, especially in the early disease state within the postulated window of opportunity. Two large foreign cohorts, including the Canadian ReACCh-Out and the Nordic cohorts have created predictive disease course models. However, to date there are limited United States data describing predictive factors for persistently active JIA early in the disease course beyond those presented in the STOP JIA trial which suggested early detection of adverse disease trajectories in polyarticular disease is possible. This study seeks to evaluate patients by both traditional ILAR and proposed PRINTO category for characteristics which may predict early JIA disease course.

Methods: We conducted a single center retrospective cohort study with 1151 JIA patients diagnosed from 2004 – 2018, excluding those with systemic onset JIA, to identify possible patient characteristics associated with active disease at 12 and 24 months post diagnosis. Patient predictor variables included: age, sex, race, ethnicity, duration of symptoms prior to diagnosis, inflamed joint count at diagnosis, serologies, uveitis status, primary language, insurance status, distance to treating rheumatologist, and early response to therapy at 3 months, as well as ILAR and PRINTO JIA category. Primary outcomes include active and inactive disease at 12 and 24 months. Inactive disease was defined by physician global assessment of 0/10 and modified Wallace criteria. Through univariate logistic regression analysis we will evaluate for predictive variables of active disease status in the first 24 months after diagnosis. A secondary multivariate logistic regression analysis will be completed based on significant univariate findings.

Results: Descriptive analysis of patient characteristics are shown in Table 1. Our population was 68% female, with 38% classified as polyarticular and 34% as oligoarticular, primarily White (75%) and non-Hispanic (77%). In the total JIA cohort, 40% (449) of patients had active disease at 12 months and 33% (328) had active disease at 24 months after diagnosis. Disease activity by JIA category demonstrates differences are present between categories when patients are categorized by both ILAR and PRINTO standards (Figure 1). Predictor analysis for outcomes is ongoing at this time.

Conclusion: Disease activity status at 12 months by ILAR category was overall similar to the Canadian cohort, and slightly lower for polyarticular patients than the STOP JIA cohort. This study is the first of its kind to evaluate patients for disease activity outcomes based on proposed PRINTO categories in comparison to ILAR categories. In our planned analysis we hypothesize that when evaluating patients by JIA category, there will be characteristic predictors, beyond JIA category, associated with higher prevalence of active disease at 12 and 24 months post diagnosis.

Supporting image 1

Supporting image 2


Disclosures: E. Balay, None; S. Shenoi, None.

To cite this abstract in AMA style:

Balay E, Shenoi S. Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/investigation-of-predictive-factors-for-active-disease-status-within-24-months-of-juvenile-idiopathic-arthritis-diagnosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigation-of-predictive-factors-for-active-disease-status-within-24-months-of-juvenile-idiopathic-arthritis-diagnosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology